Clinico-Molecular Risk Stratification in 284 Patients With Pre-Fibrotic and Overt Myelofibrosis

被引：0
|
作者：
Chang, Yu-Sung [1 ]
Wang, Yu-Hung [1 ,2 ]
Wei, Chao-Hung [3 ,4 ]
Lin, Chien-Chin [1 ,5 ]
Yuan, Chang-Tsu [6 ]
Tsai, Cheng-Hong [1 ,7 ]
Liu, Jia-Hau [8 ]
Ko, Bor-Sheng [8 ]
Yao, Ming [8 ]
Tien, Hwei-Fang [1 ,9 ]
Chou, Wen-Chien [1 ,5 ]
Hou, Hsin-An [1 ,10 ]
机构：
[1] Natl Taiwan Univ Hosp, Div Hematol, Dept Internal Med, Taipei, Taiwan
[2] Univ Manchester, Div Canc Sci, Epigenet Haematopoiesis Lab, Manchester, England
[3] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsinchu, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan
[6] Natl Taiwan Univ, Dept Pathol, Canc Ctr, Taipei, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Med Educ & Res, Yunlin Branch, Touliu, Yunlin, Taiwan
[8] Natl Taiwan Univ, Canc Ctr, Dept Hematol Oncol, Taipei, Taiwan
[9] Far Eastern Mem Hosp, Dept Internal Med, New Taipei, Taiwan
[10] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MPN; myelofibrosis; genetic mutation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-239
引用
收藏
页码：S424 / S424
页数：1
相关论文
共 50 条
  • [21] Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature
    Almanza, Diego
    Gharaee-Kermani, Mehrnaz
    Zhilin-Roth, Alisa
    Rodriguez-Nieves, Jose A.
    Colaneri, Cory
    Riley, Todd
    Macoska, Jill A.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (05) : 1257 - 1269
  • [22] Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification
    Gill, Harinder
    Au, Lester
    Leung, Garret Man Kit
    Tsai, Dorothy
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Sin, Albert Chun Fung
    Hou, Hsin An
    Chen, Chih-Cheng
    Kwong, Yok Lam
    BLOOD, 2023, 142
  • [23] How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024
    Griesshammer, Martin
    Al-Ali, Haifa Kathrin
    Eckardt, Jan-Niklas
    Fiegl, Michael
    Goethert, Joachim
    Jentsch-Ullrich, Kathleen
    Koschmieder, Steffen
    Kvasnicka, Hans Michael
    Reiter, Andreas
    Schmidt, Burkhard
    Heidel, Florian H.
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 295 - 306
  • [24] Clinical Features and Outcomes of Pre-Fibrotic Primary Myelofibrosis Patients with Triple-Negative, JAK2V617F and Calr Mutations
    Hu, Shiwei
    Xiang, Danhong
    Yang, Min
    Huang, Jian
    BLOOD, 2022, 140 : 3957 - 3958
  • [25] A CLINICO-MOLECULAR RISK STRATIFICATION MODEL FOR RESECTED GASTRIC CANCER: PROGNOSTIC IMPACT OF HER2, FHIT AND APC EXPRESSION STATUS
    Bria, E.
    De Manzoni, G.
    Beghelli, S.
    Tomezzoli, A.
    Barbi, S.
    Frizziero, M.
    Sperduti, I.
    Bersani, S.
    Tortora, G.
    Scarpa, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 226 - 227
  • [26] Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
    Kjaer, Lasse
    Skov, Vibe
    Larsen, Morten Kranker
    Boklund, Tobias Idor
    Andersen, Morten
    Kefala, Maria
    Knudsen, Trine A.
    Schjellerup Eickhardt-Dalboge, Christina
    Stiehl, Thomas
    Gudmand-Hoyer, Johanne
    Snyder, Jordan
    Holmstrom, Morten
    Andersen, Mads H.
    Ottesen, Johnny T.
    Ellervik, Christina
    Hasselbalch, Hans C.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [27] A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
    Steen, Chloe B.
    Leich, Ellen
    Myklebust, June H.
    Lockmer, Sandra
    Wise, Jillian F.
    Wahlin, Bjorn E.
    Ostenstad, Bjorn
    Liestol, Knut
    Kimby, Eva
    Rosenwald, Andreas
    Smeland, Erlend B.
    Holte, Harald
    Lingjaerde, Ole Christian
    Brodtkorb, Marianne
    HAEMATOLOGICA, 2019, 104 (10) : E460 - E464
  • [28] DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy
    Prelaj, A.
    Proto, C.
    Lo Russo, G.
    Signorelli, D.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Randon, G.
    Pagani, F.
    Travisan, B.
    Ganzinelli, M.
    Zilembo, N.
    De Braud, F. G. M.
    Mensah, M.
    Torri, V.
    Garassino, M. C.
    Sozzi, G.
    Boeri, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
    Jeryczynski, Georg
    Thiele, Juergen
    Gisslinger, Bettina
    Woelfler, Albert
    Schalling, Martin
    Gleiss, Andreas
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Sliwa, Thamer
    Schloegl, Ernst
    Geissler, Klaus
    Krauth, Maria-Theresa
    Nader, Alexander
    Vesely, Michael
    Simonitsch-Klupp, Ingrid
    Muellauer, Leonhard
    Beham-Schmid, Christine
    Gisslinger, Heinz
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (09) : 885 - 891
  • [30] Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis - case report and systematic review of dabigatran use
    Di Pilla, Marina
    Barco, Stefano
    Sacco, Clara
    Barosi, Giovanni
    Lodigiani, Corrado
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2021, 50 (02) : 151 - 156
12345